You are here

Lilly pauses Covid-19 antibody treatment trial over safety concern

nz_elililly_141042.jpg
US pharmaceutical firm Eli Lilly on Tuesday paused a late-stage trial of its experimental lab-produced antibody treatment against Covid-19 over an unspecified safety concern, the company said.

[WASHINGTON] US pharmaceutical firm Eli Lilly on Tuesday paused a late-stage trial of its experimental lab-produced antibody treatment against Covid-19 over an unspecified safety concern, the company said.

"Lilly is supportive of the decision by the independent DSMB (data safety...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes